Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Rises By 10.0%

GoodRx Holdings, Inc. (NASDAQ:GDRX) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 9,030,000 shares, a growth of 10.0% from the August 15th total of 8,210,000 shares. Currently, 11.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,370,000 shares, the short-interest ratio is currently 6.6 days.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GoodRx

Institutional investors have recently bought and sold shares of the company. Beacon Capital Management LLC purchased a new position in shares of GoodRx in the first quarter valued at approximately $28,000. Plato Investment Management Ltd acquired a new stake in GoodRx in the 2nd quarter valued at about $43,000. Dark Forest Capital Management LP purchased a new stake in shares of GoodRx during the 2nd quarter worth $86,000. Gerber LLC acquired a new position in shares of GoodRx during the fourth quarter worth $75,000. Finally, Schnieders Capital Management LLC acquired a new stake in GoodRx in the first quarter valued at $93,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Trading Down 3.2 %

Shares of GoodRx stock traded down $0.24 on Wednesday, reaching $7.35. The company had a trading volume of 1,060,207 shares, compared to its average volume of 1,452,858. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. The firm has a market cap of $2.76 billion, a PE ratio of -735.00, a PEG ratio of 3.55 and a beta of 1.38. The firm’s 50 day moving average price is $8.00 and its two-hundred day moving average price is $7.60. GoodRx has a 52-week low of $4.14 and a 52-week high of $9.26.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The firm had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. During the same quarter last year, the company earned $0.02 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Sell-side analysts predict that GoodRx will post 0.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GDRX has been the subject of several research analyst reports. Morgan Stanley upped their price target on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research report on Monday, June 10th. UBS Group dropped their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Citigroup decreased their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research note on Friday, August 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.36.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.